11 / 32
Events
262 ADT alone | 184 ADT+AA+P
HR
0.63
95% CI
0.52 to 0.76
P-value
<0.001
STAMPEDE: OS “AA+P comparison”
James N et al. J Clin Oncol 2017;35(15):LBA5003 (suppl)
James N et al. N Engl J Med 2017;377(4):338-351
3-year survival:
- 83% with ADT+AA+P
- 76% with ADT-alone
ADT+AA+P
ADT alone
This represents a 37%
improvement in survival
Events
262 ADT alone | 184 ADT+AA+P
HR
95%
P-val
STAMPEDE: OS “AA+P comparison”
James N et al. J Clin On
3-y
- 8
- 7
ADT+AA+P
ADT alone
This
imp